CO5031291A1 - PHARMACEUTICAL COMPOSITION - Google Patents

PHARMACEUTICAL COMPOSITION

Info

Publication number
CO5031291A1
CO5031291A1 CO97052280A CO97052280A CO5031291A1 CO 5031291 A1 CO5031291 A1 CO 5031291A1 CO 97052280 A CO97052280 A CO 97052280A CO 97052280 A CO97052280 A CO 97052280A CO 5031291 A1 CO5031291 A1 CO 5031291A1
Authority
CO
Colombia
Prior art keywords
controlled release
dosage form
oral
pharmaceutical composition
carboxymethylamide
Prior art date
Application number
CO97052280A
Other languages
Spanish (es)
Inventor
Susan Marie Milosovich
William Muldoon
James Albert Napper
Laurence Rousseau
Joseph Sauer
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of CO5031291A1 publication Critical patent/CO5031291A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Una forma de dosificación oral de liberación controlada quecontiene el monohidrocloruro de [R-(Z)]-a-(metoxiimino)-a-(1-azabiciclo[2.2.2]oct-3-il) acetonitrilo(compuesto X), su base libre original o cualquier otra de sus sales farmacéuticamente aceptables.Una forma de dosificación de acuerdo con cualquiera de las reivindicaciones precedentes, que comprende una matriz hinchable y/o gelificable seleccionada entre alquilcelulosas, hidroxialquilcelulosas, poli(alcohol vinílico), polimetacrilatos, poli(metacrilatos de metilo), copolímeros de metacrilato/divinilbenceno, carboximetilamida, polioxialquilenglicoles, polivinilpirrolidona y carboximetilcelulosa.1Un método de tratamiento y/o profilaxis de la demencia, incluyendo la enfermedad de Alzheimer, en mamíferos, administrando una cantidad efectiva de una forma de dosificación oral de liberación controlada de acuerdo con la reivindicación 1, a un paciente que lo necesite.An oral controlled release dosage form containing [R- (Z)] -a- (methoxyimino) -a- (1-azabicyclo [2.2.2] oct-3-yl) acetonitrile monohydrochloride (compound X), its Original free base or any other pharmaceutically acceptable salts thereof. A dosage form according to any of the preceding claims, comprising an inflatable and / or gellable matrix selected from alkylcelluloses, hydroxyalkylcelluloses, polyvinyl alcohol, polymethacrylates, poly ( methyl methacrylates), methacrylate / divinylbenzene, carboxymethylamide, polyoxyalkylene glycols, polyvinyl pyrrolidone and carboxymethyl cellulose copolymers. 1 A method of treatment and / or prophylaxis of dementia, including Alzheimer's disease, in mammals, by administering an effective amount of one oral form of controlled release according to claim 1, to a patient in need.

CO97052280A 1996-09-12 1997-09-09 PHARMACEUTICAL COMPOSITION CO5031291A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9619074.9A GB9619074D0 (en) 1996-09-12 1996-09-12 Composition

Publications (1)

Publication Number Publication Date
CO5031291A1 true CO5031291A1 (en) 2001-04-27

Family

ID=10799833

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97052280A CO5031291A1 (en) 1996-09-12 1997-09-09 PHARMACEUTICAL COMPOSITION

Country Status (22)

Country Link
EP (1) EP0929301A2 (en)
JP (1) JP2001500150A (en)
KR (1) KR20000036039A (en)
CN (2) CN1235544A (en)
AR (1) AR008176A1 (en)
AU (1) AU724086B2 (en)
BR (1) BR9711734A (en)
CA (1) CA2265661A1 (en)
CO (1) CO5031291A1 (en)
CZ (1) CZ83299A3 (en)
GB (1) GB9619074D0 (en)
HU (1) HUP9904401A3 (en)
ID (1) ID19589A (en)
IL (1) IL128781A0 (en)
MA (1) MA24359A1 (en)
NO (1) NO991194D0 (en)
NZ (1) NZ334268A (en)
PE (1) PE2499A1 (en)
PL (1) PL332074A1 (en)
TR (1) TR199900505T2 (en)
WO (1) WO1998010762A2 (en)
ZA (1) ZA978133B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (en) * 1998-03-04 2001-04-20 Gattefosse Ets Sa ORAL PELLET ADAPTED TO IMPROVE THE BIOAVAILABILITY OF THE ACTIVE SUBSTANCE, METHOD OF MANUFACTURE
IL138192A0 (en) * 1998-03-11 2001-11-25 Smithkline Beecham Plc Controlled release oral dosage forms
DE19918325A1 (en) * 1999-04-22 2000-10-26 Euro Celtique Sa Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives
FR2796840B1 (en) 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques LOW-DOSE TABLETS AND METHOD OF PREPARATION
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
AR040682A1 (en) 2002-07-25 2005-04-13 Pharmacia Corp DOSAGE FORM ONCE A DAY OF PRAMIPEXOL
JP4808612B2 (en) * 2003-04-25 2011-11-02 田辺三菱製薬株式会社 Composition for oral administration containing alkylenedioxybenzene derivative
EP1628642B2 (en) * 2003-05-14 2013-01-23 Aptalis Pharma Limited Controlled drug release composition resistant to in vivo mechanic stress
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (en) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk Method for producing solid preparation
JP4785847B2 (en) 2004-08-13 2011-10-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Tablet formulation with extended release comprising pramipexole or a pharmaceutically acceptable salt thereof, process for its production and use thereof
BRPI0513848A (en) * 2004-08-13 2008-05-20 Boehringer Ingelheim Int Pramipexole prolonged-release pellet formulation or a pharmaceutically acceptable salt thereof, method of manufacture thereof and use thereof
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69034146T2 (en) * 1989-04-13 2005-07-14 Beecham Group P.L.C., Brentford Chemical compounds
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (en) * 1995-07-29 1998-11-04 Smithkline Beecham Plc PROCEDURE FOR THE FORMULATION OF A PHARMACY, A PHARMACEUTICAL COMPOSITION OBTAINABLE THROUGH THIS PROCEDURE AND THE USE OF THE SAME.

Also Published As

Publication number Publication date
CN1235544A (en) 1999-11-17
AR008176A1 (en) 1999-12-09
WO1998010762A2 (en) 1998-03-19
CN1446535A (en) 2003-10-08
NZ334268A (en) 2000-10-27
NO991194L (en) 1999-03-11
AU724086B2 (en) 2000-09-14
BR9711734A (en) 1999-08-24
NO991194D0 (en) 1999-03-11
MA24359A1 (en) 1998-07-01
CA2265661A1 (en) 1998-03-19
PL332074A1 (en) 1999-08-30
AU4128897A (en) 1998-04-02
ID19589A (en) 1998-07-23
EP0929301A2 (en) 1999-07-21
GB9619074D0 (en) 1996-10-23
WO1998010762A3 (en) 1998-06-04
TR199900505T2 (en) 1999-06-21
KR20000036039A (en) 2000-06-26
HUP9904401A3 (en) 2001-03-28
HUP9904401A2 (en) 2000-06-28
IL128781A0 (en) 2000-01-31
CZ83299A3 (en) 1999-08-11
PE2499A1 (en) 1999-03-24
JP2001500150A (en) 2001-01-09
ZA978133B (en) 1999-04-12

Similar Documents

Publication Publication Date Title
NO179250C (en) Analogous Process for Preparation of Therapeutically Active (+) - (2,3-Dimethoxyphenyl) -1- [2- (4-Fluorophenyl) Ethyl α-4-Piperidinemethanol
CO5031291A1 (en) PHARMACEUTICAL COMPOSITION
MX9405219A (en) NEW PHARMACEUTICAL FORMULATION.
CY1106072T1 (en) ORAL EXTENDED RELEASE DOSAGE FORM
AR064896A2 (en) NON-HYGROSCOPIC PHARMACEUTICAL COMPOSITION
LU91147I2 (en) Pemetrexed and its pharmaceutically acceptable salts.
ES2180251T3 (en) COMPRESSED COVERED WITH POLYMER, CONTAINING AMOXYCLINE AND CLAVULANATE.
NO943761L (en) Orally administered extended-duration opioid formulations
DK372786D0 (en) PHARMACEUTICAL PREPARATIONS OF PHENINDAMINE
MX9203278A (en) SUSTAINED RELEASE PILL INCLUDING LORATADINE, IBUPROFEN AND PSEUDOEFEDRINE.
GR1000465B (en) Process for manufacturing pharmaceutical compositions comprising acetyl d-carnitine for the therapeutic treatment of glaucoma
SE9500422D0 (en) New oral pharmaceutical dosage forms
ATE198835T1 (en) BONE GROWTH-PROMOTING COMPOSITION
DK0503440T3 (en) Sumatriptan-containing medicines
RU2000131897A (en) ORAL DOSING COMPOSITION OF PROLONGED ACTION
NL980008I1 (en) Use of sertindole to treat schizophrenia.
ATE260262T1 (en) PHARMACEUTICALLY ACTIVE BENZOQUINAZOLINE COMPOUNDS
AR026968A1 (en) A MATRIX TABLET THAT ALLOWS THE PROLONGED TRIMETAZIDINE RELEASE AFTER YOUR ADMINISTRATION BY ORAL ROUTE
HUP0004282A2 (en) 2-halo-6-0-substituted ketolide derivatives
NO178338C (en) Analogous Process for Preparing a Therapeutically Active Benzimidazole Compound and Intermediate
FR2735369B1 (en) PHARMACEUTICAL COMPOSITIONS BASED ON SODIUM SALT OF DICLOFENAC AND THIOCOLCHICOSIDE
EP0670166A3 (en) Formulations for orally administered pharmaceutical agents.
AR002191A1 (en) ORAL PHARMACEUTICAL COMPOSITION OF PIPERIDINOALCANOL COMPOUNDS IN THE FORM OF SOLUTION, PROCEDURE FOR ITS PREPARATION
DE69012031T2 (en) Optically active benzyl alcohol compound and pharmaceutical composition.
LU90110I2 (en) Penciclovir and its pharmaceutically acceptable derivatives